KCIC
NVO

Kuhn & Co Investment Counsel’s Novo Nordisk NVO Stock Holding History

Kuhn & Co Investment Counsel’s Portfolio NVO Stock Details NVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-3,970
Closed -$220K – 146
2025
Q3 		$220K Hold
3,970
– – 0.17% 118
2025
Q2 		$274K Buy
3,970
+85
+2% +$5.78K 0.21% 113
2025
Q1 		$270K Buy
3,885
+85
+2% +$7.02K 0.23% 113
2024
Q4 		$327K Sell
3,800
-22
-0.6% -$2.38K 0.28% 101
2024
Q3 		$455K Hold
3,822
– – 0.39% 86
2024
Q2 		$546K Buy
3,822
+22
+0.6% +$2.92K 0.49% 68
2024
Q1 		$488K Buy
+3,800
New +$452K 0.46% 77

Other funds holding NVO

Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
F
Folketrygdfondet Oslo Norway, Norway $5.64B AUM 47.16% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Kuhn & Co Investment Counsel's NVO Position: Q4 2025 in Review

Kuhn & Co Investment Counsel sold out of Novo Nordisk (NVO) in Q4 2025, closing a stake of 3,970 shares — an estimated $220K sold.

Kuhn & Co Investment Counsel first reported a position in NVO in Q1 2024 and held it in 7 quarters. The position peaked at $546K in Q2 2024. 1,414 funds tracked by Wall St. Rank hold NVO as of Q4 2025.

  • Kuhn & Co Investment Counsel reported no remaining Novo Nordisk position as of Q4 2025 after selling out during the quarter.
  • Kuhn & Co Investment Counsel sold 3,970 Novo Nordisk shares in Q4 2025, an estimated $220K.
  • Kuhn & Co Investment Counsel first reported a position in Novo Nordisk in Q1 2024 and held it in 7 quarters.
  • Kuhn & Co Investment Counsel's Novo Nordisk position peaked at $546K in Q2 2024.
  • 1,414 funds tracked by Wall St. Rank held Novo Nordisk as of Q4 2025.

Based on Kuhn & Co Investment Counsel's 13F filing for Q4 2025, filed 9 Feb 2026.